Megan Sniecinski - 01 Jan 2026 Form 3 Insider Report for Praxis Precision Medicines, Inc. (PRAX)

Role
Chief Operating Officer
Signature
/s/ Alex Nemiroff, as Attorney-in-Fact
Issuer symbol
PRAX
Transactions as of
01 Jan 2026
Net transactions value
$0
Form type
3
Filing time
09 Jan 2026, 16:37:04 UTC
Next filing
12 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sniecinski Megan Chief Operating Officer C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON /s/ Alex Nemiroff, as Attorney-in-Fact 09 Jan 2026 0001781480

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PRAX Common Stock 20,877 01 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRAX Stock Option (Right to Buy) 01 Jan 2026 Common Stock 11,999 $257.25 Direct F2
holding PRAX Stock Option (Right to Buy) 01 Jan 2026 Common Stock 821 $31.80 Direct F3
holding PRAX Stock Option (Right to Buy) 01 Jan 2026 Common Stock 9,999 $44.40 Direct F4
holding PRAX Stock Option (Right to Buy) 01 Jan 2026 Common Stock 30,000 $43.37 Direct F5
holding PRAX Stock Option (Right to Buy) 01 Jan 2026 Common Stock 36,400 $56.94 Direct F6
holding PRAX Stock Option (Right to Buy) 01 Jan 2026 Common Stock 22,500 $63.15 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes: (i) 5,805 unvested Restricted Stock Units ("RSUs") from an award of 7,800 RSUs granted on July 29, 2024, which vests in equal annual installments over a four-year period beginning on January 12, 2025; and (ii) 11,250 RSUs granted on January 10, 2025, which vests in equal annual installments over a four-year period beginning on January 10, 2026. The RSUs may be settled only by delivering shares of the Issuer's common stock, and thus, both grants are being reported in Table 1 as allowed per SEC guidance.
F2 This option is fully vested.
F3 The shares underlying this stock option vest over a four-year period, with 25% vested on June 22, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.
F4 The shares underlying this stock option vest over a four-year period, with 25% vested on January 12, 2024 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.
F5 The shares underlying this stock option vest as follows: 50% vested in full on January 12, 2024 (the "Grant Date") and the remaining 50% vesting over a four-year period, with 25% of such shares vesting on the first anniversary of the Grant Date and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.
F6 The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the reporting person's continued service through each vesting date.
F7 The shares underlying this stock option vest over a four-year period, with 25% vesting on January 10, 2026 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney